Coban, AYAkbal, AUBicmen, CAlbay, ASig, AKUzun, MSelale, DSOzkutuk, NSurucuoglu, SAlbayrak, NUcarman, NOzkutuk, AEsen, NCeyhan, IOzyurt, MBektore, BAslan, GDelialioglu, NAlp, A2024-07-182024-07-182045-2322http://akademikarsiv.cbu.edu.tr:4000/handle/123456789/10620The aim of this multicenter study was to evaluate the performance of the crystal violet decolorization assay (CVDA) for detection of multidrug resistant tuberculosis (MDR-TB). This study was performed in 11 centers in two phases. A total of 156 isolates were tested for INH and RIF resistance. In the phase I, 106 clinical isolates were tested in the Center 1-7. In the phase 2, 156 clinical isolates were tested in the center 1-6, center 8-11. Eighty six of 156 tested isolates were the same in phase I. Agreements were 96.2-96.8% for INH and 98.1-98.7% for RIF in the phase I-II, respectively. Mean time to obtain the results in the phase I was 14.3 +/- 5.4 days. In the phase II, mean time to obtain the results was 11.6 +/- 3.5 days. Test results were obtained within 14days for 62.3% (66/106) of isolates in the phase I and 81.4% (127/156) of isolates in the phase II. In conclusion, CVDA is rapid, reliable, inexpensive, and easy to perform for rapid detection of MDR-TB isolates. In addition, it could be adapted for drug susceptibility testing with all drugs both in developed and developing countries.EnglishNITRATE REDUCTASE ASSAYRESAZURIN MICROTITER ASSAYMALACHITE GREENSTREPTOMYCIN RESISTANCEMULTIDRUG-RESISTANTSUSCEPTIBILITYETHAMBUTOLPLATEArticle